Physician profile
Mark W Wolfe
NPI 1962500322
$2,696.83
in general payments reported to CMS, 2019-2025
19 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $81.05 · 2021: $99.51 · 2022: $304 · 2023: $342 · 2024: $546 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,959 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.70 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $433.93 | 2019-2025 | |
| Amgen INC. | $401.87 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $269.09 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $216.21 | 2020-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $178.32 | 2022-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $161.48 | 2025 | Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $158.02 | 2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $125.82 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $125.25 | 2021-2025 | Onpattro, Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.46 | 2019-2025 | Jardiance |
| Boston Scientific Corporation | $104.77 | 2019-2023 | Watchman |
| Heartflow, INC. | $85.83 | 2024-2025 | |
| Esperion Therapeutics, INC. | $64.83 | 2021-2025 | Nexletol |
| Scpharmaceuticals INC. | $58.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $55.05 | 2020-2024 | Farxiga |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $49.83 | 2019 | |
| Janssen Scientific Affairs, LLC | $47.04 | 2022 | |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Gilead Sciences, INC. | $20.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.